Lebanese American University

HOUSTON, Aug. 13, 2024 /PRNewswire/ -- The American Society for Preventive Cardiology (ASPC) previously announced the development of a 2-year fellowship program to support the creation of cardiometabolic training programs nationwide and increase the number of expert clinicians equipped to effectively manage patients with cardiometabolic risk factors. The ASPC is pleased to announce that the world-renowned Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease will host the first ASPC Cardiometabolic Medicine Fellow. Dr. Yara Jelwan started her training on July 1, 2024 with Dr. Michael Blaha as program director. Dr. Jelwan studied at the Lebanese American University in Beirut, continued her education receiving an MPH in methodology and statistics in Paris, and is currently a Post-Graduate Year 3 Internal Medicine resident at St. Lukes Hospital in St. Louis. Dr. Jelwan's notable work at St. Luke's Hospital includes enhancing Coronary Artery Calcium scoring and addressing the underutilization of SGLT2 inhibitors and GLP1 receptor agonists. "Thank you to the ASPC for this wonderful opportunity!" Dr. Jelwan stated. "I am excited to be a part of a new tradition of cardiometabolic training within preventive cardiology." The rate of metabolic diseases – obesity, metabolic syndrome, diabetes mellitus – have been steadily increasing in the United States and across the globe. In 2019, of the 37 million people in the U.S. who were estimated to have diabetes, nearly 25% of them were undiagnosed, and the total number is expected to triple by 2060.1,2 The number of U.S. adults in 2020 with obesity and severe obesity are projected to increase from 42% to 50% and 18% to 25% respectively in 2030.3 The rate of metabolic syndrome has increased 25% from 1988 to 2012, representing a third of the U.S. population.4 Historically, the care of cardiometabolic diseases has been fragmented between primary care physicians and specialists such as endocrinologists, cardiologists, and less often hepatologists and nephrologists.5 This approach has been characterized by sparse interaction among specialists and lack of ownership of the field by any specialty or type of physician. As a result, the cardiometabolic patient is left without a "home", instead being shuffled between specialty clinics. "There is a recognition that we are undertreating cardiometabolic disease in our high-risk cardiovascular patients," Dr. Blaha commented. "This is an important step toward our vision of more widespread cardiometabolic medicine training in the U.S.". The ASPC is a non-profit membership-based association dedicated to educating health care professionals and patients about the prevention of cardiovascular diseases. For more information about ASPC, please visit . References: Lin J, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018 Jun 15;16(1):9. Ward ZJ, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019 Dec 19;381(25):2440-2450. Saxon DR, et al. Cardiometabolic Medicine: Development of a New Subspecialty. J Clin Endocrinol Metab. 2020 Jul 1;105(7). SOURCE The American Society for Preventive Cardiology

DENVER, June 9, 2022 /PRNewswire/ -- Today Leiters has announced that Memorial Hermann Health System – a non-profit, community-focused, award-winning health system committed to creating healthier Houston communities – has joined the company's growing list of strategic health system investor partners, which was led by a majority investment from Welsh, Carson, Anderson & Stowe (WCAS). Leiters provides high-quality compounded sterile preparations and pharmacy services across the healthcare continuum to a growing number of hospitals, surgery centers and physician offices. Leiters offers an end-to-end suite of product types including pre-filled syringes, IV bags and concentrated vials; pain services including opioid free medications; pharmacy fill service for the ON-Q* Pain Relief System; and ophthalmic medications and services including, FDA-Compliant Repackaged Avastin®. Robin Smith Hoke, Leiters' President and Chief Executive Officer said, "We are very pleased to welcome Memorial Hermann to our team of health system investor partners. We look forward to working closely with their leadership to meet their needs. The investment enables us to continue to increase capacity, expand our portfolio and ensure the continued delivery of high-quality medications to the healthcare market." Memorial Hermann joins Leiters' existing health system investors including Intermountain Ventures, Kaiser Permanente Ventures, Mayo Clinic, Novant Health, Rex Health Ventures, Spectrum Health Ventures and UNC Health. "As a non-profit, values-driven, community-owned health system, Memorial Hermann takes its dual roles of being a responsible financial steward and a trusted healthcare provider extremely seriously," said Feby Abraham, EVP and Chief Strategy Officer at Memorial Hermann Health System. "By making prudent investments in companies that align with our mission to improve health, we ensure we can continue meeting the needs of our Greater Houston community, one of the largest and fastest-growing metropolitan areas of the country, while also creating greater efficiencies in our operations. The decision to invest in Leiters is guided by the same philosophies that drive all of our work: deliver value and create healthier communities." Memorial Hermann is one of the largest not-for-profit health systems in Southeast Texas. While practicing the highest standards of safe, evidence-based, quality care, the system's 6,500 affiliated physicians and 29,000 employees provide a personalized and outcome-oriented experience across more than 265 care delivery sites throughout the Greater Houston area. Memorial Hermann, along with the existing health system investors, will participate in Leiters' Strategic Pharmacy Advisory Board to support growth initiatives, continuous quality improvement, new product development and investments in enabling capabilities. About Leiters Leiters is a trusted FDA-registered 503B outsourcing provider of high-quality compounded sterile preparations and pharmacy services. It is committed to providing healthcare professionals and their patients with critically needed outsourced medications. Its team of experts in sterile pharmaceutical manufacturing, repackaging and compounding provide a sophisticated understanding of what it takes to elevate quality and consistency of supply in pharmaceutical outsourcing. Leiters combines a highly experienced team, with robust automated processes, in a state-of-the-art outsourcing facility, to ensure delivery of the highest quality medicines. All sterile preparations are produced under the Human Drug Outsourcing Facilities under 503B of the FD&C Act (503B Guidance) and follow Current Good Manufacturing Practices (cGMP). To learn more about how Leiters is Compounding Health™ please visit . About Memorial Hermann Health System Charting a better future. A future that's built upon the HEALTH of our community. This is the driving force for Memorial Hermann, redefining health care for the individuals and many diverse populations we serve. Our 6,500 affiliated physicians and 29,000 employees practice the highest standards of safe, evidence-based, quality care to provide a personalized and outcome-oriented experience across our more than 265 care delivery sites. As one of the largest not-for-profit health systems in Southeast Texas, Memorial Hermann has an award-winning and nationally acclaimed Accountable Care Organization, 17* hospitals and numerous specialty programs and services conveniently located throughout the Greater Houston area. Memorial Hermann-Texas Medical Center is one of the nation's busiest Level I trauma centers and serves as the primary teaching hospital for McGovern Medical School at UTHealth. For more than 115 years, our focus has been the best interest of our community, contributing more than $400 million annually through school-based health centers and other community benefit programs. Now and for generations to come, the health of our community will be at the center of what we do – charting a better future for all. *Memorial Hermann Health System owns and operates 14 hospitals and has joint ventures with three other hospital facilities, including Memorial Hermann Surgical Hospital First Colony, Memorial Hermann Surgical Hospital Kingwood and Memorial Hermann Rehabilitation Hospital-Katy. About Welsh, Carson, Anderson & Stowe WCAS is a leading U.S. private equity firm focused on the healthcare and technology industries. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives, and strategic acquisitions. The firm has raised and managed funds totaling over $30 billion of committed capital. For more information, please visit . WCAS Contacts: Jon Rather 212-893-9570 [email protected] Greg Lau 212-893-9586 [email protected] Leiters Contact: Kari Cashmore 720-414-7216 [email protected] Memorial Hermann Contact: [email protected] SOURCE Leiters

Jan. 27, 2021 11:25 UTC - Nabil Shabshab to Succeed Scott Wilkinson as President and CEO and Join the Board of Directors Effective February 8, 2021 - GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed Nabil Shabshab as Inogen’s President and Chief Executive Officer (“CEO”), effective February 8, 2021. In addition, Mr. Shabshab was appointed to the Board of Directors, effective February 8, 2021. Mr. Shabshab will succeed Scott Wilkinson, who is retiring as President, CEO, and as a director, in each case effective February 8, 2021. Heath Lukatch, Ph.D., Inogen’s Chairman, said, “On behalf of the Board of Directors, I would like to congratulate Nabil on this appointment and thank Scott for his significant contributions to Inogen over the last fifteen years. During Scott’s tenure with the company, Inogen became the market leader in portable oxygen concentrators, with best-in-class products and an innovative go to market approach. Nabil is a highly talented and experienced executive who we believe will be critical to Inogen’s plans for growth, as we continue to work towards improving the lives of respiratory therapy patients.” “I am honored for the opportunity to lead Inogen in our mission to increase the freedom and independence for respiratory patients and to make our technologies the standard of care,” said Mr. Shabshab. “I look forward to driving the next phase of Inogen’s success as we continue to seek ways to increase patient access to our technologies, expand the impact we have on patients, drive growth business, and increase value for our stockholders.” “I am grateful to have led this outstanding company and to be a part of improving almost a million patients’ lives with our innovative portable oxygen concentrators,” said Mr. Wilkinson. “As I previously disclosed, this is the right time for me personally to retire as CEO, and I believe that Inogen will continue to increase patient and physician awareness of our products while also focusing on providing excellent service.” Most recently, Mr. Shabshab, 56, has served as Worldwide President of Diabetes Care and Digital Health at Becton Dickinson and Company, a leading medical technology company, since August 2017. Prior to that, since August 2011, Mr. Shabshab served as Becton Dickinson’s Chief Marketing Officer and Executive Vice President of Strategic Planning. Prior to Becton Dickinson, Mr. Shabshab served as EVP, Global Portfolio, Chief Marketing Officer and Head of RD&E of Diversey, Inc., a cleaning and sanitation solutions company from 2006 to 2010. In his previous roles Mr. Shabshab served as Principal with The Zyman Group, as Vice President, Client Solutions and Consulting with Symphony IRI, and in various sales and marketing roles in pharmaceutical and consumer goods companies including Warner Lambert / Pfizer, the Coca-Cola Company, and Fronterra. Mr. Shabshab holds an MBA from Northwestern University Kellogg School of Management and a B.S. in Computer Sciences from American Lebanese University. About Inogen We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. For more information, please visit . Cautionary Note About Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced management and organizational changes, statements concerning or implying Inogen’s future financial performance, trends and opportunities affecting Inogen, and the ability of management personnel and our board of directors to contribute to increasing patient access to our products and technologies, expanding our business, and increasing value for our stockholders. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks related to its announced management and organizational changes, risks arising from the possibility that Inogen will not realize anticipated revenue; the risks related to the COVID-19 public health emergency; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; risks relating to Inogen’s acquisition of New Aera and the integration of New Aera’s business and operations within those of Inogen; risks relating to reimbursement coding of the Tidal Assist© Ventilator (TAV); the possibility that Inogen will not realize anticipated revenue from the technology acquired from New Aera or that expenses and costs will exceed Inogen’s expectations; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products; and intellectual property risks relating to the acquisition of New Aera, including the risk of intellectual property litigation. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and its subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.